Longevity.Technology Spotlights Unlimited Bio’s Bold Gene Therapy Strategy
Longevity.Technology profiled Unlimited Bio, highlighting its VEGF therapy in Próspera, upcoming follistatin and combination trials, and a bold goal of 100 studies in 10 years, positioning the company as a fast-moving biotech innovator.
September 11, 2025 — Longevity.Technology
Longevity.Technology, one of the leading global media outlets covering longevity science, profiled Unlimited Bio in its feature “Keeping up with the longevity gene therapies.” The article underscored the company’s pioneering use of Special Economic Zones (SEZs) to accelerate preventive gene therapy innovation.
Highlights include:
- Launch of a VEGFtherapy at the company’s Próspera ZEDE clinic (Roatán, Honduras), designed for vascular rejuvenation.
- Upcoming follistatin gene therapy and plans for combination trials tackling multiple hallmarks of aging.
- An ambitious roadmap of 100 clinical or real-world trials in 10 years.
- Strategy of starting with therapies that already have established safety profiles, minimizing risk while enabling early patient access.
This recognition from Longevity.Technology strengthens Unlimited Bio’s image as a fast-moving challenger in longevity biotech, proving that entrepreneurial approaches can rival billion-dollar institutions in the race to extend human healthspan.
Vladimir Leshko
2025-09-11 08:28
